Illumina Future Growth
Future criteria checks 3/6
Illumina is forecast to grow earnings and revenue by 68.4% and 7.6% per annum respectively. EPS is expected to grow by 68.3% per annum. Return on equity is forecast to be 9.4% in 3 years.
Key information
68.4%
Earnings growth rate
68.3%
EPS growth rate
| Life Sciences earnings growth | 16.4% |
| Revenue growth rate | 7.6% |
| Future return on equity | 9.4% |
| Analyst coverage | Good |
| Last updated | 22 Apr 2024 |
Recent future growth updates
Recent updates
Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)
Mar 20
Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition
Feb 23Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Jan 26Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024
Jan 19Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%
Dec 21Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?
Dec 03Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?
Oct 24Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?
Oct 03At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?
Aug 22The Big Trends: New Frontiers in Healthcare
Jul 13
Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)
Jul 03Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt
Jun 13Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?
Apr 12Is Illumina (NASDAQ:ILMN) Using Too Much Debt?
Mar 14Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?
Dec 30Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?
Dec 02These 4 Measures Indicate That Illumina (NASDAQ:ILMN) Is Using Debt Reasonably Well
Oct 27Illumina, GenoScreen collaborate on genomic testing for drug-resistant TB
Oct 18Illumina in research collaboration with AstraZeneca on drug target discovery
Oct 11Illumina Engages Obama To Push Its Customers' Reimbursement Agenda
Sep 29Illumina to appeal EU decision to block GRAIL acquisition
Sep 06Illumina Needs Grail, But May Lose It
Aug 30Illumina added to positive catalyst watch at Citi despite Q2 miss
Aug 22Illumina up 9% following drop after Q2 earnings
Aug 15Is It Too Late To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?
Aug 08Still Avoiding Illumina Stock
Aug 05Illumina, Grail deal unlikely to get EU nod – Reuters
Jul 27Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 48% Discount?
Jul 22Ensemble Capital Management - Illumina: Never Been So Cheap
Jul 19Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,413 | 556 | 854 | 998 | 10 |
| 12/31/2025 | 4,955 | 271 | 721 | 932 | 18 |
| 12/31/2024 | 4,515 | -114 | 358 | 579 | 19 |
| 12/31/2023 | 4,504 | -1,161 | 282 | 478 | N/A |
| 10/1/2023 | 4,465 | -1,125 | 168 | 401 | N/A |
| 7/2/2023 | 4,461 | -4,186 | -224 | 210 | N/A |
| 4/2/2023 | 4,448 | -4,487 | -228 | 230 | N/A |
| 1/1/2023 | 4,584 | -4,404 | -74 | 392 | N/A |
| 10/2/2022 | 4,700 | -4,153 | 79 | 527 | N/A |
| 7/3/2022 | 4,693 | -20 | 53 | 307 | N/A |
| 4/3/2022 | 4,656 | 701 | 208 | 435 | N/A |
| 1/2/2022 | 4,526 | 762 | 337 | 545 | N/A |
| 10/3/2021 | 4,280 | 907 | 469 | 669 | N/A |
| 7/4/2021 | 3,966 | 769 | 898 | 1,094 | N/A |
| 4/4/2021 | 3,473 | 630 | 890 | 1,081 | N/A |
| 1/3/2021 | 3,239 | 656 | 891 | 1,080 | N/A |
| 9/27/2020 | 3,238 | 638 | 933 | 1,117 | N/A |
| 6/28/2020 | 3,351 | 693 | 1,046 | 1,231 | N/A |
| 3/29/2020 | 3,556 | 942 | 941 | 1,134 | N/A |
| 12/29/2019 | 3,543 | 1,002 | 842 | 1,051 | N/A |
| 9/29/2019 | 3,458 | 973 | 691 | 908 | N/A |
| 6/30/2019 | 3,405 | 938 | 701 | 933 | N/A |
| 3/31/2019 | 3,397 | 851 | 823 | 1,085 | N/A |
| 12/30/2018 | 3,333 | 826 | 846 | 1,142 | N/A |
| 9/30/2018 | 3,243 | 684 | 829 | 1,136 | N/A |
| 7/1/2018 | 3,103 | 648 | 752 | 1,079 | N/A |
| 4/1/2018 | 2,936 | 567 | 643 | 962 | N/A |
| 12/31/2017 | 2,752 | 725 | 563 | 875 | N/A |
| 10/1/2017 | 2,594 | 775 | N/A | 843 | N/A |
| 7/2/2017 | 2,487 | 741 | N/A | 784 | N/A |
| 4/2/2017 | 2,424 | 730 | N/A | 848 | N/A |
| 1/1/2017 | 2,398 | 454 | N/A | 779 | N/A |
| 10/2/2016 | 2,371 | 440 | N/A | 757 | N/A |
| 7/3/2016 | 2,314 | 430 | N/A | 762 | N/A |
| 4/3/2016 | 2,253 | 415 | N/A | 692 | N/A |
| 1/3/2016 | 2,220 | 462 | N/A | 786 | N/A |
| 9/27/2015 | 2,141 | 510 | N/A | 560 | N/A |
| 6/28/2015 | 2,071 | 486 | N/A | 524 | N/A |
| 3/29/2015 | 1,979 | 430 | N/A | 531 | N/A |
| 12/28/2014 | 1,861 | 353 | N/A | 501 | N/A |
| 9/28/2014 | 1,736 | 281 | N/A | 488 | N/A |
| 6/29/2014 | 1,612 | 219 | N/A | 425 | N/A |
| 3/30/2014 | 1,511 | 208 | N/A | 336 | N/A |
| 12/29/2013 | 1,421 | 125 | N/A | 386 | N/A |
| 9/29/2013 | 1,343 | 117 | N/A | 338 | N/A |
| 6/30/2013 | 1,272 | 115 | N/A | 307 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ILMN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: ILMN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ILMN is expected to become profitable in the next 3 years.
Revenue vs Market: ILMN's revenue (7.6% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: ILMN's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ILMN's Return on Equity is forecast to be low in 3 years time (9.4%).